
LLY
Eli Lilly and Company
Pharmaceutical company focused on oncology, immunology, neuroscience. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
10
$86.30M
Insider Sales
46
$2.29B
Total Volume
$2.37B
100 transactions
Net Activity
$2.20B
Net selling
Sentiment Rating
Strong AccumulationCEO Conviction Index
High Conviction Accumulation
Key Drivers
- •Heavy distribution: sales represent 96% of total transaction value.
- •Cluster buying: 10 unique insiders purchased shares, showing strong alignment.
- •CEO buying activity detected. When chief executives put their own money at risk, it is historically a strong bullish signal.
- •CFO buying activity detected. Statistical studies show CFO purchases have high predictive power due to their direct visibility into balance sheet details.
- •Ultra-high accumulation: total purchase value exceeds $10M.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Lilly Endowment Inc
Former 10% Shareholder
$2.25B total
Multiple Insiders
S - Sale Insiders
$1.16B total
David Ricks
CEO
$41.28M total
Afshin Mehra
CFO
$40.49M total
Board Director
Dir
$32.64M total
Quick Actions
LLY has an insider buy conviction of 4%, compared to the Pharmaceuticals sector buy average of 0%.
Over the last 90 days, corporate insiders at Eli Lilly and Company (LLY) engaged in a total of 100 transactions reported via SEC Form 4 filings. Among these, 10 were open-market purchases and 46 were sales. The total volume of insider trading reached $2.37B.
The net insider activity for LLY shows a net selling bias of $2.20B. This activity represents a 4% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 677.0K shares valued at $1.10B on Aug 12, 2025.
Eli Lilly (LLY) After ObesityWeek Is The Stock Still Undervalued
Lilly vs. Pfizer: Which Drugmaker Has Stronger Growth Prospects?
Was Eli Lilly Stock’s 45% Run Visible Early?
Eli Lilly (NYSE:LLY): Strong Growth Paired With a High-Quality Technical Setup
Rhythm Pharmaceuticals gains on report Eli Lilly made $150/share offer with CVR (RYTM:NASDAQ)
Eli Lilly hikes sales outlook, as CEO says there's room for 'dramatic' obesity market expansion
Explore Peers in Drug Manufacturers
Compare insider activity and sentiment scores across similar organizations.
Related News & Analyst Reports
Read original insights and educational research covering Eli Lilly and Company and the Drug Manufacturers sector.
The AI Circular Valuation Bubble: Inside the Venture-Cloud Loop
An in-depth investigation into how technology giants and AI startups engage in circular capital flows, investing venture capital in exchange for cloud services and hardware, creating a closed-loop economy that artificially inflates valuations.
Sequoia Capital and the Mechanics of Venture Lock-Up Extensions
Sequoia Capital pioneered the use of voluntary lock-up extensions to signal portfolio company confidence. This report analyzes the market-price impact of Sequoia extension announcements and whether they have historically justified the delay.
The Role of Insider Trading in M&A: Deciphering the Pre-Merger Signals
M&A deals are the most fertile ground for illegal insider trading, and for legal cluster buys that signal a company is strategically attractive. This guide separates the legal signal from the illegal noise in M&A-adjacent Form 4 activity.
Venture-Backed Biotech IPOs: Inside the 2026 Buying Spree
2026 saw a resurgence of venture-backed biotech IPOs, accompanied by unusually high post-lockup insider buying. This report documents the specific Form 4 cluster events, purchase sizes, and 90-day price performance across a dozen recent biotech offerings.
Biotech Insider Buying: Analyzing Clinical Trial Catalysts
Biotech insiders walk a legal tightrope near trial readouts. This report identifies statistically significant buying clusters at small-cap biotechs 30-90 days before Phase 2 and Phase 3 data announcements.
Deciphering Option Exercises (Code M) vs. Open Market Purchases (Code P)
Transaction code M (option exercise) is often mistaken for bullish conviction, but it usually means nothing. Learn why Code P open-market purchases are the only Form 4 entries that signal genuine insider belief.
FAQs About Eli Lilly and Company Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for LLY.

